Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15–55 years

The HPV-16/18 AS04-adjuvanted vaccine (Cervarix(®), GlaxoSmithKline Biologicals) has been shown to induce a robust immune response in women aged 15–55 years (103514/NCT00196937). This follow-up study is the first report of persistence of immune response and safety profile through 48 months after vac...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Schwarz, Tino F, Spaczynski, Marek, Schneider, Achim, Wysocki, Jacek, Galaj, Andrzej, Schulze, Karin, Poncelet, Sylviane, Catteau, Gregory, Thomas, Florence, Descamps, Dominique
Formato: Artigo
Idioma:Inglês
Publicado: Landes Bioscience 2011
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3225769/
https://ncbi.nlm.nih.gov/pubmed/21892005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.7.9.15999
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares